Arrowhead grabs RNAi delivery assets in Roche deal

Arrowhead Research ($ARWR) has parachuted into the bombarded field of RNAi therapeutics armed with Swiss drug giant Roche's assets. As part of Pasadena, CA-based Arrowhead's acquisition of Roche's stake in the gene-silencing drugs, the firm picked up three drug-delivery technologies. The technologies include a delivery platform called "Dynamic PolyCunjugates" (DPCs), a license to "SNALP" delivery tech from Tekmira Pharamceuticals ($TKM), and Roche-developed liposomal nanoparticle RNAi carriers. Roche is among several Big Pharma groups that have made major cuts to internal research of RNAi drugs. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.